**Study Overview:** Multiple Myeloma (MM) is a type of blood cancer that affects the plasma cells in bone marrow. This study is testing a new drug, BMS-986393, to see if it's safe and works well when used with other drugs like alnuctamab, mezigdomide, and iberdomide. The study is for people whose cancer has come back (relapsed) or didn't respond to treatment (refractory). **Key Points:** - **Duration and Visits:** Study involves multiple visits over time to monitor safety and effectiveness. - **Compensation:** Participants may receive compensation for their time and travel. - **Eligibility:** Must have had at least 1-3 previous treatments for MM and meet certain health criteria. **Eligibility Details:** Participants need to have measurable MM and a good performance status, meaning they can carry on with regular daily activities. Some conditions might exclude you from participating, such as problems with the brain or spinal cord related to MM. Always check all criteria before deciding to join.